284 related articles for article (PubMed ID: 16321761)
1. Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Taphoorn MJ; Stupp R; Coens C; Osoba D; Kortmann R; van den Bent MJ; Mason W; Mirimanoff RO; Baumert BG; Eisenhauer E; Forsyth P; Bottomley A; ; ;
Lancet Oncol; 2005 Dec; 6(12):937-44. PubMed ID: 16321761
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
[TBL] [Abstract][Full Text] [Related]
4. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
7. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Reijneveld JC; Taphoorn MJB; Coens C; Bromberg JEC; Mason WP; Hoang-Xuan K; Ryan G; Hassel MB; Enting RH; Brandes AA; Wick A; Chinot O; Reni M; Kantor G; Thiessen B; Klein M; Verger E; Borchers C; Hau P; Back M; Smits A; Golfinopoulos V; Gorlia T; Bottomley A; Stupp R; Baumert BG
Lancet Oncol; 2016 Nov; 17(11):1533-1542. PubMed ID: 27686943
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Osoba D; Brada M; Yung WK; Prados M
J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Reddy K; Gaspar LE; Kavanagh BD; Waziri A; Damek DM; Ney D; Lillehei KO; Chen C
J Neurooncol; 2013 Aug; 114(1):111-6. PubMed ID: 23729276
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
[TBL] [Abstract][Full Text] [Related]
12. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
13. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
[TBL] [Abstract][Full Text] [Related]
14. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
Heutte N; Flechtner HH; Mounier N; Mellink WA; Meerwaldt JH; Eghbali H; van't Veer MB; Noordijk EM; Kluin-Nelemans JC; Lampka E; Thomas J; Lugtenburg PJ; Viterbo L; Carde P; Hagenbeek A; van der Maazen RW; Smit WG; Brice P; van Marwijk Kooy M; Baars JW; Poortmans P; Tirelli U; Leeksma OC; Tomsic R; Feugier P; Salles G; Gabarre J; Kersten MJ; Van Den Neste E; Creemers GJ; Gaillard I; Meijnders P; Tertian G; Reman O; Muller HP; Troncy J; Blanc M; Schroyens W; Voogt PJ; Wijermans P; Rieux C; Fermé C; Henry-Amar M;
Lancet Oncol; 2009 Dec; 10(12):1160-70. PubMed ID: 19828373
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study.
Lombardi G; Bergo E; Del Bianco P; Bellu L; Pambuku A; Caccese M; Trentin L; Zagonel V
Am J Clin Oncol; 2018 Dec; 41(12):1263-1271. PubMed ID: 29750673
[TBL] [Abstract][Full Text] [Related]
18. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Armstrong TS; Wefel JS; Wang M; Gilbert MR; Won M; Bottomley A; Mendoza TR; Coens C; Werner-Wasik M; Brachman DG; Choucair AK; Mehta M
J Clin Oncol; 2013 Nov; 31(32):4076-84. PubMed ID: 24101048
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
